Disease: Candida infections

Drug repurposing to fight resistant fungal species: Recent developments as novel therapeutic strategies

mycolabadmin

Fungal infections are becoming increasingly difficult to treat due to growing drug resistance, affecting millions of people worldwide each year. This research collection explores creative solutions by repurposing existing medications and developing new combination therapies that work better together against resistant fungal species. Studies show promising results combining common antibiotics like minocycline with antifungal drugs, and natural compounds from traditional medicine show potential for treating hard-to-treat infections like Candida and Aspergillus.

Read More »

John Perfect Shares Insights on Infectious Diseases, Antifungal Therapy, and Drug Resistance

mycolabadmin

This interview with Dr. John Perfect, a leading expert in fungal infections, discusses how antifungal treatments have evolved over his 48-year career. He explains that while fungal resistance is a concern, it’s less problematic than bacterial antibiotic resistance because fungi don’t spread resistance through plasmids. Dr. Perfect emphasizes the importance of newer, faster-acting antifungal drugs and combining drug therapy with immune system support to better treat serious fungal infections like cryptococcal meningitis and candidemia.

Read More »

Glycan microarray analysis of Candida-related antibodies in human and mice sera guides biomarker discovery and vaccine development

mycolabadmin

Researchers developed a test using synthetic sugar molecules found on Candida yeast to detect antibodies in blood from infected patients and mice. They discovered that the immune system produces different antibodies at different stages of infection, starting with antibodies against certain sugars and later focusing on others. The study identified three specific sugar structures that could be used to create simple blood tests to diagnose Candida infections and potentially develop vaccines to prevent these serious fungal infections.

Read More »

Unveiling the hidden arsenal: exploring secondary metabolites and fungal development in pathogenic fungi

mycolabadmin

Dangerous fungi produce hidden chemical compounds that help them infect humans and crops while also potentially serving as medicines. Scientists are studying how these compounds work and how fungi make them to develop better treatments and protect our food supply. This editorial highlights recent research showing that understanding fungal chemistry from genetic, ecological, and medical perspectives will help us fight fungal diseases as resistance increases.

Read More »

Is metabolic generalism the Breakfast of Champions for pathogenic Candida species?

mycolabadmin

This review examines how different Candida species, including the common cause of yeast infections (C. albicans) and the more dangerous bloodstream pathogen (C. glabrata), survive in the human body. While most pathogenic Candida species are metabolic generalists that can eat many different nutrients, the review shows that C. glabrata is a specialist that has found alternative strategies to thrive. Understanding these metabolic strategies is important for developing better treatments and fighting antifungal resistance.

Read More »
Scroll to Top